What's Happening?
Codis, a global contract development and manufacturing organization, has announced the acquisition of Catalent's facility in Nottingham, UK. This acquisition aims to create Europe's leading end-to-end spray dry capability, enhancing Codis' particle engineering
expertise. The Nottingham site will add oral solid dose development and small-scale manufacturing capabilities, complementing Codis' existing facilities. This strategic move is expected to strengthen Codis' position in the market by providing integrated spray dry solutions from development to commercial production. The acquisition is set to close in Q3 2026, subject to customary closing conditions.
Why It's Important?
The acquisition of Catalent's Nottingham facility by Codis represents a strategic expansion of its capabilities in the pharmaceutical manufacturing sector. By integrating development and manufacturing processes, Codis aims to reduce the risks associated with scaling up production, thereby enhancing the efficiency and reliability of drug development. This move is likely to benefit pharmaceutical companies seeking comprehensive solutions for improving drug bioavailability. Additionally, the acquisition underscores the growing importance of advanced manufacturing technologies in the pharmaceutical industry, as companies strive to meet the increasing demand for innovative drug delivery systems.
